Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom.
J Immunol. 2013 Apr 1;190(7):3798-805. doi: 10.4049/jimmunol.1203194. Epub 2013 Feb 27.
Alternatively activated macrophages express the pattern recognition receptor scavenger receptor A (SR-A). We demonstrated previously that coculture of macrophages with tumor cells upregulates macrophage SR-A expression. We show in this study that macrophage SR-A deficiency inhibits tumor cell migration in a coculture assay. We further demonstrate that coculture of tumor-associated macrophages and tumor cells induces secretion of factors that are recognized by SR-A on tumor-associated macrophages. We tentatively identified several potential ligands for the SR-A receptor in tumor cell-macrophage cocultures by mass spectrometry. Competing with the coculture-induced ligand in our invasion assay recapitulates SR-A deficiency and leads to similar inhibition of tumor cell invasion. In line with our in vitro findings, tumor progression and metastasis are inhibited in SR-A(-/-) mice in two in vivo models of ovarian and pancreatic cancer. Finally, treatment of tumor-bearing mice with 4F, a small peptide SR-A ligand able to compete with physiological SR-A ligands in vitro, recapitulates the inhibition of tumor progression and metastasis observed in SR-A(-/-) mice. Our observations suggest that SR-A may be a potential drug target in the prevention of metastatic cancer progression.
alternatively activated macrophages express the pattern recognition receptor scavenger receptor A (SR-A). We demonstrated previously that coculture of macrophages with tumor cells upregulates macrophage SR-A expression. We show in this study that macrophage SR-A deficiency inhibits tumor cell migration in a coculture assay. We further demonstrate that coculture of tumor-associated macrophages and tumor cells induces secretion of factors that are recognized by SR-A on tumor-associated macrophages. We tentatively identified several potential ligands for the SR-A receptor in tumor cell-macrophage cocultures by mass spectrometry. Competing with the coculture-induced ligand in our invasion assay recapitulates SR-A deficiency and leads to similar inhibition of tumor cell invasion. In line with our in vitro findings, tumor progression and metastasis are inhibited in SR-A(-/-) mice in two in vivo models of ovarian and pancreatic cancer. Finally, treatment of tumor-bearing mice with 4F, a small peptide SR-A ligand able to compete with physiological SR-A ligands in vitro, recapitulates the inhibition of tumor progression and metastasis observed in SR-A(-/-) mice. Our observations suggest that SR-A may be a potential drug target in the prevention of metastatic cancer progression.
alternatively activated macrophages 表达模式识别受体 scavenger receptor A (SR-A)。我们之前已经证明,巨噬细胞与肿瘤细胞共培养会上调巨噬细胞 SR-A 的表达。我们在本研究中表明,巨噬细胞 SR-A 缺失会抑制共培养测定中的肿瘤细胞迁移。我们进一步证明,肿瘤相关巨噬细胞与肿瘤细胞的共培养会诱导肿瘤相关巨噬细胞上被 SR-A 识别的因子分泌。通过质谱法,我们在肿瘤细胞-巨噬细胞共培养物中暂定鉴定了几种潜在的 SR-A 受体配体。在我们的侵袭测定中与共培养诱导的配体竞争,可重现 SR-A 缺失,并导致肿瘤细胞侵袭的类似抑制。与我们的体外发现一致,在卵巢癌和胰腺癌的两种体内模型中,SR-A(-/-)小鼠的肿瘤进展和转移受到抑制。最后,用 4F(一种能够在体外与生理 SR-A 配体竞争的小分子 SR-A 配体)治疗荷瘤小鼠,可重现 SR-A(-/-)小鼠中观察到的肿瘤进展和转移抑制。我们的观察结果表明,SR-A 可能是预防转移性癌症进展的潜在药物靶点。